Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT04305496

PHASE3

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Official title: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor

Key Details

Gender

All

Age Range

18 Years - 130 Years

Study Type

INTERVENTIONAL

Enrollment

818

Start Date

2020-04-16

Completion Date

2026-06-22

Last Updated

2026-01-29

Healthy Volunteers

Conditions

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Interventions

DRUG

Fulvestrant

Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter

DRUG

Capivasertib

400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle

DRUG

Placebo

Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle

Inclusion Criteria: 1. Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue on it for the duration of the study 2. Histologically confirmed HR+/HER2- breast cancer determined from the most recent tumour sample (primary or metastatic), as per the American Society of Clinical Oncology and College of American Pathologists guideline recommendations. To fulfil the requirement of HR+ disease, a breast cancer must express ER with or without co-expression of progesterone receptor. 3. Metastatic or locally advanced disease with radiological or objective evidence of recurrence or progression (the cancer should have shown progression during or after most recent therapy); locally advanced disease must not be amenable to resection with curative intent (patients who are considered suitable for surgical or ablative techniques following potential down-staging with study treatment are not eligible) 4. ECOG/WHO PS: 0-1 5. Patients are to have received treatment with an AI (aromatase inhibitor) containing regimen (single agent or in combination) and have: 1. Radiological evidence of breast cancer recurrence or progression while on, or within 12 months of the end of (neo)adjuvant treatment with an AI, OR 2. Radiological evidence of progression while on prior AI administered as a treatment line for locally advanced or metastatic breast cancer (this does not need to be the most recent therapy) 6. Patients must have measurable disease according to RECIST 1.1 and/or at least 1 lytic or mixed (lytic + sclerotic) bone lesion that can be assessed by CT or MRI; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible 7. FFPE tumour sample from primary/recurrent cancer for central testing Exclusion Criteria: 1. Symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgement 2. More than 2 lines of endocrine therapy for inoperable locally advanced or metastatic disease 3. More than 1 line of chemotherapy for inoperable locally advanced or metastatic disease. Adjuvant and neoadjuvant chemotherapy are not classed as lines of chemotherapy for advanced breast cancer 4. Prior treatment with any of the following: 1. AKT, PI3K and mTOR inhibitors 2. Fulvestrant, and other SERDs 3. Any other chemotherapy, immunotherapy, immunosuppressant medication (other than corticosteroids) or anticancer agents within 3 weeks prior to study treatment initiation. 4. Potent inhibitors or inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort) or drugs that are sensitive to CYP3A4 inhibition within 1 week prior to study treatment initiation. 5. Radiotherapy with a wide field of radiation up to 4 weeks before study treatment initiation (capivasertib/placebo) and/or radiotherapy with a limited field of radiation for palliation up to 2 weeks before study treatment initiation (capivasertib/placebo) 6. With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment 7. Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids up to 4 weeks before study treatment initiation 8. Any of the following cardiac criteria: 1. Mean resting QT interval corrected by Fridericia's formula (QTcF) \>470 msec obtained from 3 consecutive ECGs 2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third degree heart block) 3. Any factors that increase the risk of corrected QT interval (QTc) prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval 4. Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) grade ≥2 5. Uncontrolled hypotension - systolic blood pressure \<90 mmHg and/or diastolic blood pressure \<50 mmHg 6. Cardiac ejection fraction outside institutional range of normal or \<50% (whichever is higher) as measured by echocardiogram (or multiple-gated acquisition \[MUGA\] scan if an echocardiogram cannot be performed or is inconclusive) 9. Clinically significant abnormalities of glucose metabolism as defined by any of the following: 1. Patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring insulin treatment 2. HbA1c ≥8.0% (63.9 mmol/mol) 10. Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular injections of fulvestrant or LHRH agonist (if applicable) 11. Currently pregnant (confirmed with positive pregnancy test) or breast-feeding

Locations (215)

Research Site

Gilbert, Arizona, United States

Research Site

Orange, California, United States

Research Site

San Francisco, California, United States

Research Site

Whittier, California, United States

Research Site

Fort Myers, Florida, United States

Research Site

Jacksonville, Florida, United States

Research Site

Westwood, Kansas, United States

Research Site

Baltimore, Maryland, United States

Research Site

Boston, Massachusetts, United States

Research Site

Rochester, Minnesota, United States

Research Site

Kansas City, Missouri, United States

Research Site

St Louis, Missouri, United States

Research Site

Paramus, New Jersey, United States

Research Site

Farmington, New Mexico, United States

Research Site

Lake Success, New York, United States

Research Site

New York, New York, United States

Research Site

Greensboro, North Carolina, United States

Research Site

Chattanooga, Tennessee, United States

Research Site

Nashville, Tennessee, United States

Research Site

Dallas, Texas, United States

Research Site

Midlothian, Virginia, United States

Research Site

Puyallup, Washington, United States

Research Site

Berazategui, Argentina

Research Site

Buenos Aires, Argentina

Research Site

La Rioja, Argentina

Research Site

Rosario, Argentina

Research Site

Viedma, Argentina

Research Site

Adelaide, Australia

Research Site

Ballarat, Australia

Research Site

Birtinya, Australia

Research Site

Box Hill, Australia

Research Site

Concord, Australia

Research Site

Kurralta Park, Australia

Research Site

North Sydney, Australia

Research Site

Orange, Australia

Research Site

Ringwood East, Australia

Research Site

South Brisbane, Australia

Research Site

Waratah, Australia

Research Site

Wendouree, Australia

Research Site

Brussels, Belgium

Research Site

Brussels, Belgium

Research Site

Charleroi, Belgium

Research Site

Edegem, Belgium

Research Site

Namur, Belgium

Research Site

Wilrijk, Belgium

Research Site

Winnipeg, Manitoba, Canada

Research Site

Kingston, Ontario, Canada

Research Site

North York, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Baoding, China

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Changchun, China

Research Site

Chongqing, China

Research Site

Chongqing, China

Research Site

Dalian, China

Research Site

Foshan, China

Research Site

Gongshu District, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Hangzhou, China

Research Site

Hangzhou, China

Research Site

Harbin, China

Research Site

Hefei, China

Research Site

Hefei, China

Research Site

Jinan, China

Research Site

Linyi, China

Research Site

Nanchang, China

Research Site

Nantong, China

Research Site

Neijiang, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shantou, China

Research Site

Shenyang, China

Research Site

Shenyang, China

Research Site

Wuhan, China

Research Site

Wuhan, China

Research Site

Wuhan, China

Research Site

Zhengzhou, China

Research Site

Besançon, France

Research Site

Brest, France

Research Site

Metz, France

Research Site

Pierre-Bénite, France

Research Site

Plerin SUR MER, France

Research Site

Pringy, France

Research Site

Rouen, France

Research Site

Strasbourg, France

Research Site

Toulouse, France

Research Site

Dresden, Germany

Research Site

Erlangen, Germany

Research Site

Essen, Germany

Research Site

Frankfurt, Germany

Research Site

Gelsenkirchen, Germany

Research Site

Hamburg, Germany

Research Site

Hamburg, Germany

Research Site

Hamburg, Germany

Research Site

Hanover, Germany

Research Site

Heidelberg, Germany

Research Site

Kiel, Germany

Research Site

Mannheim, Germany

Research Site

Minden, Germany

Research Site

München, Germany

Research Site

München, Germany

Research Site

Münster, Germany

Research Site

Paderborn, Germany

Research Site

Potsdam, Germany

Research Site

Budapest, Hungary

Research Site

Budapest, Hungary

Research Site

Debrecen, Hungary

Research Site

Kecskemét, Hungary

Research Site

Szekszárd, Hungary

Research Site

Szolnok, Hungary

Research Site

Afula, Israel

Research Site

Beersheba, Israel

Research Site

Haifa, Israel

Research Site

Jerusalem, Israel

Research Site

Jerusalem, Israel

Research Site

Kfar Saba, Israel

Research Site

Petah Tikva, Israel

Research Site

Ramat Gan, Israel

Research Site

Bergamo, Italy

Research Site

Candiolo, Italy

Research Site

Catanzaro, Italy

Research Site

Livorno, Italy

Research Site

Macerata, Italy

Research Site

Meldola, Italy

Research Site

Milan, Italy

Research Site

Modena, Italy

Research Site

Naples, Italy

Research Site

Prato, Italy

Research Site

Roma, Italy

Research Site

Chiba, Japan

Research Site

Fukuoka, Japan

Research Site

Fukushima, Japan

Research Site

Hidaka-shi, Japan

Research Site

Hiroshima, Japan

Research Site

Kagoshima, Japan

Research Site

Kitaadachi-gun, Japan

Research Site

Kōtoku, Japan

Research Site

Kumamoto, Japan

Research Site

Kyoto, Japan

Research Site

Matsuyama, Japan

Research Site

Nagoya, Japan

Research Site

Nagoya, Japan

Research Site

Osaka, Japan

Research Site

Osaka, Japan

Research Site

Ota-shi, Japan

Research Site

Sapporo, Japan

Research Site

Sapporo, Japan

Research Site

Shinagawa-ku, Japan

Research Site

Tsu, Japan

Research Site

Yokohama, Japan

Research Site

Arequipa, Peru

Research Site

Lima, Peru

Research Site

Bydgoszcz, Poland

Research Site

Krakow, Poland

Research Site

Olsztyn, Poland

Research Site

Warsaw, Poland

Research Site

Moscow, Russia

Research Site

Moscow, Russia

Research Site

Saint Petersburg, Russia

Research Site

Saint Petersburg, Russia

Research Site

Samara, Russia

Research Site

Sochi, Russia

Research Site

Busan, South Korea

Research Site

Daegu, South Korea

Research Site

Goyang-si, South Korea

Research Site

Incheon, South Korea

Research Site

Seongnam-si, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Suwon, South Korea

Research Site

Suwon, South Korea

Research Site

A Coruña, Spain

Research Site

Barcelona, Spain

Research Site

Barcelona, Spain

Research Site

Córdoba, Spain

Research Site

Hosp de Llobregat(Barcelona), Spain

Research Site

Jaén, Spain

Research Site

La Laguna (Tenerife), Spain

Research Site

Lleida, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Majadahonda, Spain

Research Site

Málaga, Spain

Research Site

Pamplona, Spain

Research Site

Reus, Spain

Research Site

Santiago de Compostela, Spain

Research Site

Seville, Spain

Research Site

Valencia, Spain

Research Site

Valencia, Spain

Research Site

Kaohsiung City, Taiwan

Research Site

Taichung, Taiwan

Research Site

Tainan, Taiwan

Research Site

Tainan, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taoyuan District, Taiwan

Research Site

Aberdeen, United Kingdom

Research Site

Bournemouth, United Kingdom

Research Site

Bristol, United Kingdom

Research Site

Cardiff, United Kingdom

Research Site

Cheltenham, United Kingdom

Research Site

London, United Kingdom

Research Site

London, United Kingdom

Research Site

Manchester, United Kingdom

Research Site

Sutton, United Kingdom

Clinical Research Directory

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (215)